KR102637496B1 - 스테이플드 및 스티치드 폴리펩티드 및 그의 용도 - Google Patents

스테이플드 및 스티치드 폴리펩티드 및 그의 용도 Download PDF

Info

Publication number
KR102637496B1
KR102637496B1 KR1020217018392A KR20217018392A KR102637496B1 KR 102637496 B1 KR102637496 B1 KR 102637496B1 KR 1020217018392 A KR1020217018392 A KR 1020217018392A KR 20217018392 A KR20217018392 A KR 20217018392A KR 102637496 B1 KR102637496 B1 KR 102637496B1
Authority
KR
South Korea
Prior art keywords
certain embodiments
formula
substituted
unsubstituted
delete delete
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217018392A
Other languages
English (en)
Korean (ko)
Other versions
KR20210076179A (ko
Inventor
그레고리 엘. 버딘
제라드 힐린스키
Original Assignee
프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 filed Critical 프레지던트 앤드 펠로우즈 오브 하바드 칼리지
Publication of KR20210076179A publication Critical patent/KR20210076179A/ko
Application granted granted Critical
Publication of KR102637496B1 publication Critical patent/KR102637496B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217018392A 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도 Active KR102637496B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361779917P 2013-03-13 2013-03-13
US61/779,917 2013-03-13
KR1020157029096A KR20150131244A (ko) 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
PCT/US2014/025544 WO2014159969A1 (en) 2013-03-13 2014-03-13 Stapled and stitched polypeptides and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157029096A Division KR20150131244A (ko) 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20210076179A KR20210076179A (ko) 2021-06-23
KR102637496B1 true KR102637496B1 (ko) 2024-02-19

Family

ID=51625302

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217018392A Active KR102637496B1 (ko) 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
KR1020157029096A Abandoned KR20150131244A (ko) 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157029096A Abandoned KR20150131244A (ko) 2013-03-13 2014-03-13 스테이플드 및 스티치드 폴리펩티드 및 그의 용도

Country Status (11)

Country Link
US (3) US10081654B2 (enExample)
EP (3) EP3391898A3 (enExample)
JP (4) JP6568515B2 (enExample)
KR (2) KR102637496B1 (enExample)
CN (2) CN110105434B (enExample)
AU (3) AU2014244232B2 (enExample)
BR (1) BR112015022872A2 (enExample)
CA (2) CA2909620C (enExample)
HK (1) HK1222555A1 (enExample)
SG (3) SG11201508431VA (enExample)
WO (1) WO2014159969A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
KR102104762B1 (ko) 2010-08-13 2020-04-24 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
CN108929375A (zh) 2011-10-18 2018-12-04 爱勒让治疗公司 拟肽大环化合物
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
KR20150082307A (ko) 2012-11-01 2015-07-15 에일러론 테라퓨틱스 인코포레이티드 이치환 아미노산 및 이의 제조 및 사용 방법
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof
US10227390B2 (en) * 2013-06-14 2019-03-12 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
JP6759109B2 (ja) 2014-05-21 2020-09-23 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｒａｓ抑制性ペプチドおよびその使用
CN106999541A (zh) 2014-09-24 2017-08-01 艾瑞朗医疗公司 拟肽大环化合物及其用途
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
EP3256484B1 (en) * 2015-02-13 2021-06-23 Agency For Science, Technology And Research Non-membrane disruptive p53 activating stapled peptides
MX2017011834A (es) 2015-03-20 2018-04-11 Aileron Therapeutics Inc Macrociclos peptidomimeticos y usos de los mismos.
CN104877672A (zh) * 2015-05-27 2015-09-02 济南大学 一种识别零价钯的双光子荧光探针及其制备方法和应用
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
AU2016287754B2 (en) 2015-07-02 2021-02-25 Dana-Farber Cancer Institute, Inc. Stabilized anti-microbial peptides
WO2017151617A1 (en) 2016-02-29 2017-09-08 Dana-Farber Cancer Institute, Inc. Stapled intracellular-targeting antimicrobial peptides to treat infection
KR102003904B1 (ko) * 2016-08-17 2019-07-25 연세대학교 산학협력단 안정화된 알파-헬릭스 이차 구조를 갖는 펩타이드-고분자 결합체 제조방법 및 이를 이용해 제조된 펩타이드-고분자 결합체
RU2762607C2 (ru) 2016-09-13 2021-12-21 Аллерган, Инк. Стабилизированные небелковые композиции клостридиального токсина
JP7305614B2 (ja) 2017-07-19 2023-07-10 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 抗生物質耐性細菌感染症の処置のための安定化抗菌ペプチド
CA3070874A1 (en) * 2017-07-25 2019-01-31 Idp Discovery Pharma, S.L. Anticancer peptides
JP2020533413A (ja) 2017-09-07 2020-11-19 フォグ ファーマシューティカルズ， インコーポレイテッド ベータ−カテニンの機能を調節する薬剤及びその方法
EP3825303A4 (en) 2018-07-17 2022-07-06 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3840766A4 (en) 2018-08-20 2022-06-22 Fog Pharmaceuticals, Inc. Collections of peptides, peptide agents, and methods of use thereof
CN109401424A (zh) * 2018-09-20 2019-03-01 永修县利君科技有限公司 一种led-uv冷光源固化的高温烧结调墨油及其制备方法
US20220226299A1 (en) 2019-03-29 2022-07-21 Nippon Chemiphar Co., Ltd. Use of t-type calcium channel blocker for treating pruritus
CA3148882A1 (en) * 2019-08-31 2021-03-04 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptide inhibitors of focal adhesion kinase activity and uses thereof
WO2021163467A1 (en) * 2020-02-14 2021-08-19 Temple University-Of The Commonwealth System Of Higher Education Linking amino acid sequences, manufacturing method thereof, and use thereof
CA3173973A1 (en) * 2020-03-04 2021-09-10 Dana-Farber Cancer Institute, Inc. Antiviral structurally-stabilized sars-cov-2 peptides and uses thereof
CN112794880B (zh) * 2020-11-17 2022-07-05 北京大学深圳研究生院 一种稳定多肽类蛋白靶向抑制剂及其用途
IL308790A (en) * 2021-06-08 2024-01-01 Fog Pharmaceuticals Inc Clamped peptides and their methods
TWI841886B (zh) * 2021-12-06 2024-05-11 王士華 生物簽章驗證系統與生物簽章驗證方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501623A (ja) 2003-11-05 2008-01-24 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたαヘリックスペプチドおよびその使用法
US20080242598A1 (en) 2004-03-19 2008-10-02 The University Of Queensland Alpha Helical Mimics, Their Uses and Methods For Their Production
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998834A (en) * 1975-03-14 1976-12-21 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-n-phenylamides and -carbamates
US4179569A (en) * 1975-03-14 1979-12-18 Janssen Pharmaceutica N.V. N-(4-piperidinyl)-N-phenylamides
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4584303A (en) * 1984-04-09 1986-04-22 The Boc Group, Inc. N-aryl-N-(4-piperidinyl)amides and pharmaceutical compositions and method employing such compounds
ZA852315B (en) * 1984-04-09 1985-11-27 Boc Inc N-aryl-n-(4-piperindinyl)amides and pharmaceutical compositions and methods employing such compounds
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
EP1251135A3 (en) 1992-04-03 2004-01-02 California Institute Of Technology High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
EP0805819B1 (en) 1994-12-29 2012-02-08 Massachusetts Institute Of Technology Chimeric dna-binding proteins
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
MX9708500A (es) 1995-05-04 1998-02-28 Scripps Research Inst Sintesis de proteinas mediante ligacion quimica nativa.
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
US5808146A (en) * 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
EP0880357A4 (en) * 1996-01-17 1999-05-12 California Inst Of Techn SYNTHESIS OF CONFORMATORICALLY RESTRICTED AMINO ACIDS, PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS BY CATALYTIC RINGCLOSE METATHESIS
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
DE69735241T2 (de) 1996-11-21 2006-11-02 Promega Corp., Madison Alkyl peptidamide für topische verwendung
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
JP2001524301A (ja) 1997-09-17 2001-12-04 ザ・ワルター・アンド・エリザ・ホール・インスティテュート・オヴ・メディカル・リサーチ 新規治療用分子
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
US6362276B1 (en) 1998-01-07 2002-03-26 Debio Recherche Pharmaceutique S.A. Degradable heterobifunctional poly(ethylene glycol) acrylates and gels and conjugates derived therefrom
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US20030190368A1 (en) 1998-03-11 2003-10-09 Roland Stoughton Methods of diagnosis and triage using cell activation measures
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
CA2368431C (en) 1999-03-29 2006-01-24 The Procter & Gamble Company Melanocortin receptor ligands
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
DE60118935D1 (de) 2000-04-24 2006-05-24 Univ Yale New Haven Dna & protein bindende miniatur proteine
EP1349929A2 (de) 2000-07-14 2003-10-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Apoptose-induzierende dna-sequenzen
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
AU2001284942A1 (en) 2000-08-16 2002-02-25 Georgetown University Medical Center Small molecule inhibitors targeted at bcl-2
WO2002064790A2 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
US6822073B2 (en) 2001-12-20 2004-11-23 Kimberly-Clark Worldwide, Inc. Modular peptide-based reagent
CA2471719A1 (en) 2001-12-31 2003-07-17 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
DE60320780D1 (de) 2002-04-22 2008-06-19 Univ Florida Funktionalisierte nanopartikel und verwendungsverfahren
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
ES2295692T3 (es) 2002-11-08 2008-04-16 F. Hoffmann-La Roche Ag Nuevos derivados de 4-alcoxioxazol sustituido como agonistas de ppar.
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
DE602004023924D1 (en) 2003-04-18 2009-12-17 Enanta Pharm Inc Ease-hemmer
US7348434B2 (en) * 2003-08-08 2008-03-25 Antony Bigot 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them
JP2007537989A (ja) 2003-10-16 2007-12-27 アプラーゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング 安定化ペプチド
ITMI20032102A1 (it) 2003-10-30 2005-04-30 Univ Degli Studi Milano Composti peptidomimetici, procedimento stereoselettivo per la loro preparazione, loro uso come intermedi di sintesi di derivati biologicamente attivi.
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
US7407929B2 (en) 2004-05-07 2008-08-05 Boston Biomedical Research Institute Leptin peptide antagonists
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
JP2008522954A (ja) 2004-08-20 2008-07-03 フィロジカ リミテッド ｃ−Ｊｕｎ二量化のペプチド阻害剤及びその使用
WO2006069001A2 (en) 2004-12-20 2006-06-29 Baylor College Of Medicine Structural requirements for stat3 binding and recruitment to phosphototyrosine ligands
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2007013050A1 (en) 2005-07-25 2007-02-01 Hadasit Medical Research Services & Development Ltd. Heparanase-derived peptide dimers and their uses as inhibitors of heparanase
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
JP5227803B2 (ja) * 2006-11-24 2013-07-03 ハイクス ラボラトリーズ合同会社 スピロキノン化合物及び医薬組成物
WO2008076904A1 (en) 2006-12-14 2008-06-26 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
US7981999B2 (en) 2007-02-23 2011-07-19 Aileron Therapeutics, Inc. Triazole macrocycle systems
KR101623985B1 (ko) 2007-03-28 2016-05-25 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
AP2009005073A0 (en) * 2007-06-29 2009-12-31 Gilead Sciences Inc Antiviral compounds
US20100273722A1 (en) 2007-08-06 2010-10-28 Yale University Modified miniature proteins
WO2009042237A2 (en) 2007-09-26 2009-04-02 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP3241846B1 (en) 2007-10-04 2022-02-23 ZymoGenetics, Inc. B7 family member zb7h6 and related compositions and methods
US20090326192A1 (en) 2008-04-08 2009-12-31 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2010011313A2 (en) 2008-07-23 2010-01-28 President And Fellows Of Harvard College Ligation of stapled polypeptides
CA2737922A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2737918A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
BRPI0920899A2 (pt) 2008-11-24 2016-04-26 Aileron Therapeutics Inc macrociclos peptidomiméticos com propriedades melhoradas
JP5731986B2 (ja) * 2008-12-09 2015-06-10 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Ｍｃｌ−１の特異的調節の方法及び組成物
MX2011006239A (es) * 2008-12-10 2011-06-28 Achillion Pharmaceuticals Inc Analogos ciclicos de peptido de 4-amino-4-oxobutanoilo, inhibidores de replica viral.
DE102009032902A1 (de) 2009-07-10 2011-01-13 Forschungsverbund Berlin E.V. Induktion von α-Helix-Konformationen in Proteinen und Peptiden
CA2768299C (en) 2009-07-13 2018-03-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
US20110223149A1 (en) 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102812167A (zh) 2009-12-30 2012-12-05 阿维拉制药公司 蛋白的配体-介导的共价修饰
US20130345397A1 (en) * 2010-05-25 2013-12-26 Andrea Robinson Methods for the synthesis of dicarba bridges in peptides
WO2011156686A2 (en) * 2010-06-11 2011-12-15 The Regents Of The University Of Colorado, A Body Corporate Method for synthesizing a cyclic multivalent peptide using a thiol-mediated reaction
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP2637680B1 (en) * 2010-11-12 2017-03-01 Dana-Farber Cancer Institute, Inc. Cancer therapies
US20140256912A1 (en) 2011-06-17 2014-09-11 President And Fellows Of Harvard College Stabilized Variant MAML Peptides and Uses Thereof
US9487562B2 (en) * 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
PT2920197T (pt) 2012-09-26 2021-06-11 Harvard College Péptidos agrafados com bloqueio de prolina e suas utilizações
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
US9493510B2 (en) 2013-01-10 2016-11-15 Noliva Therapeutics Llc Peptidomimetic compounds
US10081654B2 (en) 2013-03-13 2018-09-25 President And Fellows Of Harvard College Stapled and stitched polypeptides and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008501623A (ja) 2003-11-05 2008-01-24 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたαヘリックスペプチドおよびその使用法
US20080242598A1 (en) 2004-03-19 2008-10-02 The University Of Queensland Alpha Helical Mimics, Their Uses and Methods For Their Production
JP2010510236A (ja) 2006-11-15 2010-04-02 ダナ−ファーバー キャンサー インスティテュート インク． 安定化させたｍａｍｌペプチドおよびその使用法

Also Published As

Publication number Publication date
EP3391898A3 (en) 2019-02-13
JP2025013736A (ja) 2025-01-27
WO2014159969A1 (en) 2014-10-02
SG10201913593WA (en) 2020-02-27
US12258423B2 (en) 2025-03-25
JP2016519059A (ja) 2016-06-30
US20220372075A1 (en) 2022-11-24
AU2014244232B2 (en) 2019-05-02
KR20150131244A (ko) 2015-11-24
HK1222555A1 (zh) 2017-07-07
EP2991665A1 (en) 2016-03-09
SG11201508431VA (en) 2015-11-27
US11332496B2 (en) 2022-05-17
US20160024153A1 (en) 2016-01-28
AU2019202458B2 (en) 2021-02-18
BR112015022872A2 (pt) 2017-11-07
CN105307667B (zh) 2019-04-19
EP3391898A2 (en) 2018-10-24
JP2023011074A (ja) 2023-01-23
SG10201700952XA (en) 2017-04-27
CA2909620C (en) 2025-07-22
JP6568515B2 (ja) 2019-08-28
EP2991665A4 (en) 2016-11-09
AU2014244232A1 (en) 2015-11-05
CN105307667A (zh) 2016-02-03
JP7216414B2 (ja) 2023-02-01
CA3085079A1 (en) 2014-10-02
AU2019202458A1 (en) 2019-05-02
CA2909620A1 (en) 2014-10-02
CN110105434A (zh) 2019-08-09
US20190202862A1 (en) 2019-07-04
CN110105434B (zh) 2024-09-17
AU2021203014A1 (en) 2021-06-10
US10081654B2 (en) 2018-09-25
KR20210076179A (ko) 2021-06-23
JP2019218363A (ja) 2019-12-26
AU2021203014B2 (en) 2023-08-31
EP3782638A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
KR102637496B1 (ko) 스테이플드 및 스티치드 폴리펩티드 및 그의 용도
EP2920197B1 (en) Proline-locked stapled peptides and uses thereof
AU2008232709B2 (en) Stitched polypeptides
JP2023518413A (ja) ヘリックス状ステープルペプチドおよびその使用
EP4238979A1 (en) Beta-strand type crosslinked peptide
HK40047860A (en) Stapled and stitched polypeptides and uses thereof
HK1262748A1 (en) Stapled and stitched polypeptides and uses thereof
BR122020012710B1 (pt) Aminoácido
HK40058717A (en) Proline derivatives
HK1213269B (en) Proline-locked stapled peptides and uses thereof

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210615

Application number text: 1020157029096

Filing date: 20151013

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210715

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211013

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211013

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220413

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20210715

Comment text: Amendment to Specification, etc.

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230209

Patent event code: PE09021S01D

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20231110

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20230809

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20220812

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20220413

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210715

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240213

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240214

End annual number: 3

Start annual number: 1

PG1601 Publication of registration